More novel target (IL23-i; Risankizumab) for #psoriaticarthritis👏. Dr Ostor presented results from Phase III KEEPsAKE2. 46% of patients were Bio-IR. 51.3% of RZB-treated vs 26.5% Placebo-tx achieved ACR20 response at 6mo (p<0.001). No major safety #EULAR2021 #OP0228 @RheumNow https://t.co/6AIGCNMApv